← Back to Search

Checkpoint Inhibitor

Sotorasib Combo vs Pembrolizumab Combo for Advanced Lung Cancer

Phase 3
Research Sponsored by Amgen
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
No history of systemic anticancer therapy in metastatic/non-curable settings
Histologically or cytologically confirmed diagnosis of nonsquamous stage IV or advanced Stage IIIB or IIIC NSCLC with KRAS p. G12C mutation and negative for PD-L1 expression by central testing or local laboratory testing confirmed through central testing
Must not have
Symptomatic (treated or untreated) brain metastases
Mixed histology NSCLC with either small-cell or large-cell neuroendocrine cell component or predominant squamous cell histology
Screening 3 weeks
Treatment Varies
Follow Up from baseline up to eos (approximately 5.5 years)
Awards & highlights


This trial compares how well two treatments keep cancer from growing or spreading in people with advanced lung cancer.

Who is the study for?
This trial is for adults with advanced non-squamous Non-Small Cell Lung Cancer (NSCLC) that has a specific mutation (KRAS p. G12C) and no PD-L1 expression. They should not have had cancer treatment in the metastatic setting, be relatively fit (ECOG ≤ 1), and able to take oral medication.Check my eligibility
What is being tested?
The study compares two treatments: Sotorasib with platinum chemotherapy versus Pembrolizumab with the same chemo, focusing on how long patients live without their cancer getting worse.See study design
What are the potential side effects?
Possible side effects include liver problems, diarrhea, muscle pain from Sotorasib; immune reactions, fatigue, skin issues from Pembrolizumab; plus typical chemo-related nausea, hair loss.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
I haven't had any systemic anticancer therapy for incurable cancer.
My advanced lung cancer is KRAS G12C mutation positive and PD-L1 negative.
I am fully active and can carry on all pre-disease activities without restriction.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
I have brain metastases that cause symptoms.
My lung cancer is mixed type with specific cell features.
I have been treated with a KRAS G12C inhibitor before.
I haven't had a heart attack or unstable heart conditions in the last 6 months.
My tumor has a specific genetic change that can be treated with approved medication.
I cannot take pills due to a stomach or intestine problem.


Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from baseline up to eos (approximately 5.5 years)
This trial's timeline: 3 weeks for screening, Varies for treatment, and from baseline up to eos (approximately 5.5 years) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Progression-free Survival (PFS)
Secondary outcome measures
Area Under The Curve (AUC) of Sotorasib
Change in Global Health Status as Measured by QLQ-C30
Change in Physical Function as Measured by QLQ-C30
+22 more

Side effects data

From 2022 Phase 1 trial • 20 Patients • NCT04887064
Electrocardiogram qt prolonged
Study treatment Arm
Severe Hepatic Impairment
Moderate Hepatic Impairment
Normal Hepatic Function

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Sotorasib combined with carboplatin and pemetrexedExperimental Treatment1 Intervention
Sotorasib administered in combination with carboplatin and pemetrexed.
Group II: Pembrolizumab combined with carboplatin and pemetrexedActive Control1 Intervention
Pembrolizumab administered in combination with carboplatin and pemetrexed.
First Studied
Drug Approval Stage
How many patients have taken this drug
Completed Phase 1

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Sotorasib is a KRAS G12C inhibitor that targets a specific mutation in the KRAS gene, halting cancer cell growth by inhibiting this mutation. Pembrolizumab is a PD-1 inhibitor that blocks the PD-1 pathway, enhancing the immune system's ability to attack cancer cells. These mechanisms are important for NSCLC patients as they allow for personalized treatment strategies based on the genetic and immune characteristics of their tumors, potentially improving treatment efficacy and patient outcomes.
The impact of smoking status on the progression-free survival of non-small cell lung cancer patients receiving molecularly target therapy or immunotherapy versus chemotherapy: A meta-analysis.Emerging therapeutic agents for lung cancer.

Find a Location

Who is running the clinical trial?

AmgenLead Sponsor
1,392 Previous Clinical Trials
1,380,370 Total Patients Enrolled
MDStudy DirectorAmgen
937 Previous Clinical Trials
926,517 Total Patients Enrolled
~500 spots leftby Feb 2026